{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:39:01Z","timestamp":1781195941614,"version":"3.54.1"},"reference-count":44,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>To estimate prevalence of continuous use (persistence) of prescribed cannabinoid medications for up to 1\u00a0year from initial prescription in Manitoba, Canada and predictors of duration of use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>A retrospective, population\u2010based, cohort study using administrative data from the Manitoba Population Research Data Repository located at the Manitoba Centre for Health Policy, Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>People without a record of a previous prescription who were prescribed a cannabinoid medication from 1 April 2004 to 1\u00a0April 2016 followed for 1\u00a0year from the date of first prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Continuous prescribed cannabinoid medication use was defined as use without a gap exceeding 60\u00a0days between prescriptions. The primary outcome was prevalence of continuous prescribed cannabinoid medication use for up to 1\u00a0year. A secondary outcome was duration of continuous use. Predictors were socio\u2010demographic characteristics, medical diagnoses and type of cannabinoid medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Among 5452 new users, 18.1% [95% confidence interval (CI)\u00a0=\u00a017.08\u201319.12] were still using cannabinoids at 1\u00a0year. Median duration of use was 31\u00a0days [interquartile range (IQR)\u00a0=\u00a025\u2013193]. This was highest for nabilone (33\u00a0days, IQR\u00a0=\u00a025\u2013199) and lowest for nabiximols (20\u00a0days, IQR\u00a0=\u00a07\u201330). Use was longest among 19\u201345\u2010 and 46\u201364\u2010year\u2010old users and those with the highest socio\u2010economic status. Fibromyalgia [hazard ratio (HR)\u00a0=\u00a00.89, 95% CI\u00a0=\u00a00.84\u20130.95], osteoarthritis (HR\u00a0=\u00a00.91, 95% CI\u00a0=\u00a00.82\u20130.97) and substance use disorder (HR\u00a0=\u00a00.85, 95% CI\u00a0=\u00a00.76\u20130.94) diagnoses were associated with longer use (HR for discontinuation\u2014HR\u00a0&lt;\u00a01 less discontinuation and longer use). A diagnosis of cancer was associated with shorter use (HR\u00a0=\u00a02.73, 95% CI\u00a0=\u00a02.02\u20133.67).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Manitoba, Canada approximately 18% of people prescribed cannabinoid medication continue using for at least 1 year. Duration of use varies with type of cannabinoid medication, age, socio\u2010economic status and dagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.14719","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T23:59:26Z","timestamp":1561507166000},"page":"1791-1799","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population\u2010based cohort study"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-0442","authenticated-orcid":false,"given":"Wajd","family":"Alkabbani","sequence":"first","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[{"name":"Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Bugden","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba  Winnipeg Manitoba Canada"},{"name":"School of Pharmacy Memorial University of Newfoundland  St John's Newfoundland Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Alessi\u2010Severini","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Bolton","sequence":"additional","affiliation":[{"name":"Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Daeninck","sequence":"additional","affiliation":[{"name":"Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-6877","authenticated-orcid":false,"given":"Christine","family":"Leong","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6358"},{"key":"e_1_2_8_3_1","first-page":"e78","article-title":"Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms","volume":"64","author":"Allan G. M.","year":"2018","journal-title":"Can Fam Physician"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001293"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2013.821477"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2013.08.010"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2004.00271.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000444234"},{"key":"e_1_2_8_9_1","unstructured":"Health Canada.Drug Product Database[internet]. The Government of Canada. Available at:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/drugs\u2010health\u2010products\/drug\u2010products\/drug\u2010product\u2010database.html(accessed April 2018) (Archived athttp:\/\/www.webcitation.org\/76WmPPZLuon 28 February 2019)."},{"key":"e_1_2_8_10_1","unstructured":"Product monograph Cesamet (nabilone)[internet]. Montreal QC: Valent Canada Limited;2009. Available at:https:\/\/pdf.hres.ca\/dpd_pm\/00007760.PDF(accessed April 2018) (Archived athttp:\/\/www.webcitation.org\/76WjwL14Mon 28 February 2019)."},{"key":"e_1_2_8_11_1","unstructured":"Product monograph Marinol (dronabinol)[internet]. Saint\u2010Laurent QC: Abbott Laboratories Limited;2011. Available at:https:\/\/pdf.hres.ca\/dpd_pm\/00013378.PDF(accessed April 2018) (Archived athttp:\/\/www.webcitation.org\/76WkI3mURon 28 February 2019)."},{"key":"e_1_2_8_12_1","unstructured":"Product monograph Sativex[internet]. Mississauga ON: Bayer Inc.;2015. Available at:https:\/\/www.bayer.ca\/omr\/online\/sativex\u2010pm\u2010en.pdf(accessed April 2018) (Archived athttp:\/\/www.webcitation.org\/76WkdBXZyon 28 February 2019)."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-7643-7358-X"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2004.00271.x"},{"key":"e_1_2_8_15_1","first-page":"180","article-title":"Medicinal cannabis: history, pharmacology, and implications for the acute care setting","volume":"42","author":"Bridgeman M. B.","year":"2017","journal-title":"Pharm Ther"},{"key":"e_1_2_8_16_1","first-page":"23","article-title":"Medication: reasons and interventions for noncompliance","volume":"31","author":"Forman L.","year":"1993","journal-title":"J Psychosoc Nurs"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.1998.130171.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04177"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02776.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1196"},{"key":"e_1_2_8_21_1","first-page":"111","article-title":"Simplified guideline for prescribing medical cannabinoids in primary care","volume":"64","author":"Allan G. M.","year":"2018","journal-title":"Can Fam Physician"},{"key":"e_1_2_8_22_1","unstructured":"Census profile 2016Census. [Internet] Statistics Canada; 2016. Available at:https:\/\/www12.statcan.gc.ca\/census\u2010recensement\/2016\/dp\u2010pd\/prof\/details\/Page.cfm(accessed April 2018) (Archived athttp:\/\/www.webcitation.org\/76WktR0tIon 28 February 2019) ."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00126-7"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2007.08.017"},{"key":"e_1_2_8_25_1","unstructured":"ATC\/DD Index[internet]. WHO Collaborating Centre for Drug Statistics;2018. Available at:https:\/\/www.whocc.no\/atc_ddd_index(accessed August 2018) (Archived athttp:\/\/www.webcitation.org\/76Wl05Dl7on 28 February 2019)."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X61875"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S138263"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1555-z"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12506"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-16"},{"key":"e_1_2_8_31_1","unstructured":"LixL. YogendranM. BurchillC. MetgeC. McKeenN. MooreD.et al.Defining and validating chronic diseases[internet]. Manitoba Centre for Health Policy;2006. Available at:http:\/\/mchp\u2010appserv.cpe.umanitoba.ca\/reference\/chronic.disease.pdf(accessed April 2018) (Archived athttp:\/\/www.webcitation.org\/76WlB3LiVon 28 February 2019) ."},{"key":"e_1_2_8_32_1","unstructured":"KatzA. MartensP. ChateauD. BogdanovicB. KosevaI. McDougallC.et al.Understanding the Health System Use of Ambulatory Care Patients. [Internet]. Manitoba Center for Health Policy;2013[internet]. Available at:http:\/\/mchp\u2010appserv.cpe.umanitoba.ca\/reference\/Amb_Care_Deliverable_Web_final.pdf(accessed April 2018) (Archived athttp:\/\/www.webcitation.org\/76WlLRpwmon 28 February 2019) ."},{"key":"e_1_2_8_33_1","unstructured":"MartensP. J. BartlettJ BurlandE. PriorH. BurchillC HuqS.et al.Profile of Metis Health Status and Healthcare Utilization in Manitoba: A Population\u2010Based Study[internet]. Manitoba Centre for Health Policy;2010. Available at:http:\/\/www.mmf.mb.ca\/docs\/metis_health_status_report.pdf(accessed April 2018) (Archived athttp:\/\/www.webcitation.org\/76WlTERh8on 28 February 2019) ."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054416"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03403825"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/80.3.557"},{"key":"e_1_2_8_37_1","first-page":"167","volume-title":"RxFiles Drug Comparison Charts","author":"Regier L.","year":"2017"},{"key":"e_1_2_8_38_1","first-page":"610","article-title":"A final report of an observational post\u2010marketing safety registry of patients primarily from the United Kingdom who have been prescribed an oromucosal spray containing \u03949\u2010tetrahydrocannabinol and cannabidiol (THC:CBD)","volume":"21","author":"Etges T.","year":"2015","journal-title":"Mult Scler"},{"key":"e_1_2_8_39_1","first-page":"184","article-title":"Observational safety study of THC: CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity","volume":"5","author":"Oreja\u2010Guevara C.","year":"2015","journal-title":"Clin Exp Pharmacol"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2695"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3290"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201439742"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.131873"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-014-0011-1"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12622"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.14719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.14719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.14719","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.14719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:48:21Z","timestamp":1780984101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.14719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/add.14719"],"URL":"https:\/\/doi.org\/10.1111\/add.14719","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"2018-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}